Ocular Surface Disease

Santen Inc. announced Thursday that the U.S. FDA has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops to treat vernal keratoconjunctivitis (VKC).

Patients who are members of racial and ethnic minority groups present clinically with worse objective measures of dry eye than patients who do not belong to these groups, new research shows.

According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.

Postop management with long-term topical antibiotics is critical to successful device retention.

Oyster Point Pharma announced today the enrollment of the first participant in its OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray to treat stage 1 neurotrophic keratopathy (NK).

The event, being held at the Mandalay Bay Resort and Casino in Las Vegas, is offering a full agenda for in-person attendees.

EyeGate Pharmaceuticals, Inc.'s lead product candidate is designed to treat dry eye disease-induced ocular surface inflammation.

Researchers seek to identify new serological biomarkers that could better characterize Sjogren’s syndrome and overcome the limitations of traditional antibodies.

Unique clinical trials and novel products of interest currently under investigation for the treatment of dry eye disease.

Patients frequently require a multidisciplinary approach.

Increased time on digital devices and erratic schedules have disrupted patients’ management of their MGD and dry eye disease.

Delivering existing therapeutics through alternative routes may offer option.

Cynthia Matossian, MD, FACS, ABES, explores the tie between mask wear and dry eye, causes behind a growing number of MGD cases, and offers mask safety tips for patient treatment.

Drops can simplify dosing, improving adherence and ocular surface health

Once-daily corticosteroid treats pain, inflammation after surgery.

Ocular symptoms in COVID-19 patients may be more common than previously thought — with sore eyes a significant sign of disease.

Cynthia Matossian, MD, FACS, ABES, continues her discussion on MGD treatment by explaining why it's important for patients to understand that MGD and dry eye are lifelong, chronic conditions requiring regular maintenance and monitoring.

Cynthia Matossian, MD, FACS, ABES, discusses the big disconnect between signs and symptoms of ocular surface disease, including meibomian gland dysfunction, and why a clear process for educating patients and initiating treatment is essential.

New options open possibilities for treatment, resulting in better outcomes for patients.

Improvements gained prior to surgery can result in positive outcomes.

Cynthia Matossian, MD, FACS, advises on how ophthalmologists can start performing a better diagnosis of ocular surface disease in three simple steps.

One ophthalmologist offers insight on how to help patients treat their dry eye symptoms when working from home amid the pandemic.

Researchers note that more study of conjunctivitis is needed in patients with COVID-19

This action will result in 2 separate companies,

First new therapy in nearly a decade offers another option for physicians, patients